Keio Innovation Initiative (headquartered in Minato-ku, Tokyo; Koutaro Yamagishi, President; hereinafter "KII") has invested in Vetanic Corporation, a startup that utilizes research results from Nihon University and Keio University, through a private placement of new shares from a fund managed by KII. Including funds raised from other investors, Vetanic will raise a total of 150 million yen through this third-party allotment.
Promote development of various regenerative medicine and other products using clinical-grade canine iPS cells
Vetanic develops various regenerative medicine products, including canine iPS cell-derived mesenchymal stem cells (MSCs). However, the use of regenerative medicine in veterinary medicine is currently limited to a small number of veterinary hospitals that meet facility requirements, and there are issues that need to be addressed in order for regenerative medicine to become widespread, such as inconsistent quality, lead time to start treatment, and high treatment costs. Through joint research with Nihon University and Keio University, the company has succeeded in producing the world's only canine iPS cells suitable for clinical use, and will promote the development of MSCs, which are currently in high demand in veterinary medicine. Furthermore, by taking advantage of the high quality, low cost, donor-free, and ethical characteristics of canine iPS cells, the company plans to sequentially launch the development of various regenerative medicine products other than MSCs. By solving the technical problems that have been encountered thus far, we will promote the spread of animal regenerative medicine and bring happiness to people through the healthy and happy lives of as many animals as possible.

*Clinical grade canine iPS cells constructed with Vetanic technology
About Vetanic Inc.
| name of company | Vetanic Inc. |
| Establishment | January 8, 2021 |
| Location | 2-2-15, Hamamatsucho 2-chome, Minato-ku, Tokyo |
| representative | Akinori Mochizuki, President and Representative Director |
| Business Overview | Research, development, manufacture and sale of regenerative medicine products for animals and research, development, manufacture and sale of reagents related to regenerative medicine |
| uniform resouce locator | U R L : https://www.vetanic.com/ Related U R L: https://www.keio.ac.jp/ja/press-releases/files/2021/4/2/210402-1.pdf |
About Keio Innovation Initiative (KII)
KII was established in July 2016 primarily to support startups that utilize the results of research at Keio University. Since January 2020, KII has expanded its investment focus to include technology startups that address social innovation through digital technology and solutions to issues such as medicine and health, with a focus on seed and early-stage lead investments, not limited to Keio University.
By investing in and fostering startups, the company contributes to society by promoting the social implementation of outstanding research results, including technologies and intellectual property from Japan's leading universities and other research institutions, while at the same time ensuring high profitability as a venture capital fund and working to build a sustainable innovation ecosystem.
| name of company | Keio Innovation Initiative, Inc. |
| Establishment | December 17, 2015 |
| capital stock | 10F Mita Kokusai Building, 1-4-28 Mita, Minato-ku, Tokyo |
| representative | Hirotaro Yamagishi, President and Representative Director |
| Business Overview | Cultivation of university-launched technology venture companies and management of venture capital funds |
| uniform resouce locator | https://www.keio-innovation.co.jp |









